US4482539A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Betamethasone dipropionate cream
Assignee: Merck Sharp & Dohme LLC
•
Filing: 1983-05-13
•
Granted: 1984-11-13
•
Expires: 2003-05-13
Abstract
Abstract Disclosed is an elegant cream-like formulation of betamethasone dipropionate useful as a topical antiinflammatory product.
Inventors
- 👤 Varda E. Sandweiss
- 👤 Elliot Stupak
- 👤 Paul H. Shapiro
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:02
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61K47/00; A61K47/02; A61K47/30; A61K47/32; A61K9/00; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
59 words
A topical pharmaceutical composition for the treatment of inflammation consisting essentially of 0.02 to 0.10 percent betamethasone dipropionate; 0.4 to 0.6 percent titanium dioxide; 1.0 to 2.5 percent Carbomer 940; sufficient base to adjust the pH to between pH 4.0 to pH 5.5; and about 60 to 80 percent of propylene glycol and about 20 to 40 percent water.
Claim 2
Dependent Claim
59 words
A topical pharmaceutical composition for the treatment of inflammation consisting essentially of 0.02 to 0.10 percent betamethasone dipropionate; 0.4 to 0.6 percent titanium dioxide; 1.0 to 2.5 percent Carbomer 940; sufficient base to adjust the pH to between pH 4.0 to pH 5.5; and about 60 to 80 percent of propylene glycol and about 20 to 40 percent water.
Claim 3
Dependent Claim
20 words
A pharmaceutical composition according to claim 1 wherein Carbomer 940 is present in an amount of about 2% by weight.
Claim 4
Dependent Claim
59 words
A pharmaceutical composition according to claim 1 consisting essentially of 0.06 to 0.08 percent betamethasone dipropionate; about 0.4 to 0.6 percent titanium dioxide; about 1.0 to 2.5 percent Carbomer 940; sufficient base to adjust the pH to between pH 4.0 to pH 5.5; and about 65 to 75 percent of propylene glycol and about 25 to 35 percent water.
Claim 5
Dependent Claim
13 words
A pharmaceutical composition according to claim 1 wherein said base is sodium hydroxide.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-11-13 | 1988-05-14 | 1988-11-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-11-13 | 1992-05-14 | 1992-11-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-11-13 | 1996-05-14 | 1996-11-13 | $7700.00 | Window Closed / Lapsed |